Find a Trial

Trial Results


17 protocol(s) meet the specified criteria
IUSCC-0705OPEN TO ACCRUAL
Informational Meetings for Planning And Coordinating Treatment (IMPACT)
NEUR-ECOG-ACRIN-EAF151OPEN TO ACCRUAL
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NSRG-IIR-COHEN-DESIOPEN TO ACCRUAL
Evaluation of intraoperative desorption electrospray ionization mass spectrometry for detection of biomolecules indicative of cancerous versus noncancerous disease state in brain tumors using pathology biopsies.
PHO-COG-ACNS1831OPEN TO ACCRUAL
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
PHO-COG-ACNS1833OPEN TO ACCRUAL
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PHO-COG-ACNS1931OPEN TO ACCRUAL
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
PHO-COG-ACNS2021OPEN TO ACCRUAL
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
PHO-COG-ANBL1821OPEN TO ACCRUAL
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-DOD-NF110OPEN TO ACCRUAL
NF110: Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
PHO-EPIZYME-EAPOPEN TO ACCRUAL
Tazemetostat Pediatric Expanded Access Program (EAP). GUIDELINES FOR PEDIATRIC PATIENTS WITH SOLID TUMORS.
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
RADY-IIR-REGITOPEN TO ACCRUAL
Registering Genomics and Imaging of Tumors
RAON-IIR-IUSCC-0710OPEN TO ACCRUAL
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
SNEU-GTMEDICAL-STARTOPEN TO ACCRUAL
A Multicenter Observational Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
SNEU-IIR-RIMTIHOPEN TO ACCRUAL
Role of Inflammatory Mediators in Tumor-Induced Hydrocephalus